Main Menu

WISER-P: Real-world testing of software for measuring bone disease on whole-body MRI in patients with prostate cancer

Disease Site: Prostate cancer

Treatment Modality: Imaging

Status: In set-up

Trial Details

WISER-P is a prospective, randomised, multi-centre, controlled trial comparing the clinical performance of whole-body MRI (WBMRI), used with novel software, and conventional imaging (CT & bone scan), to assess treatment response of bone disease in patients with bone predominant metastatic castration resistant prostate cancer (mCRPC).

126 patients will be recruited from 8-10 UK sites over an 18 month period. All patients will undergo imaging, according to their randomised group, prior to commencement of systemic treatment and again at 8-9 weeks from start of treatment and patients will be followed up for a minimum 12 months from start of treatment.

Further Information

Chief Investigator: Professor Dow-Mu Koh. The Royal Marsden NHS Trust.

ICR-CTSU Scientific Lead: Dr Nuria Porta

Trial Management Contact: [email protected]

ISRCTN: 54072577

Sponsor: The Institute of Cancer Research

Funding: National Institute for Health Research i4i (Invention for Innovation) Challenge Award

View WISER-P on the National Institute for Health Research website: NIHR - Be Part Of Research.

A lay summary in plain English will soon be available from Cancer Research UK.

Publications and Presentations

There have been no presentations or publications to date.

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.